RESUMO
The study aimed to evaluate the retinal ganglion cell structure using optical coherence tomography and the visual pathway function employing visual evoked potentials in the diagnosis and monitoring of patients with pituitary macroadenoma. A descriptive, cross-sectional, and longitudinal study (3 and 12 months follow-up) was conducted on forty-two patients. Thirty-five age-matched healthy controls were used in the cross-sectional one. Full neuro-ophthalmological evaluation (structural and functional) was carried out including global and segmented retinal nerve fiber layer/ganglion cell complex analysis and amplitude and latency of P100 component in the electrophysiology. Statistical data analysis was conducted with R version 3.6.3 and Python version 3.8. Associations were evaluated using Spearman's correlations. Amplitude sensitivities were 0.999, and bi-nasal sectors of ganglion cell complex thickness specificities were 0.999. This structural parameter had the highest diagnostic value (area under curve = 0.923). Significant associations were found between bi-nasal sectors with amplitude at 12' (rho > 0.7, p < 0.01) and median deviation of the visual field (rho > 0.5, p < 0.01) at 3 months. Pre-surgical values of bi-nasal sectors and amplitude can predict post-surgically median deviation and amplitude (Oz, 12') at 3 months with r 2 > 0.5. Bi-nasal sectors of ganglion cell complex and visual evoked potentials P100 amplitude are efficient biomarkers of visual pathway damage for pituitary macroadenoma patients' management. Pre-surgical values of the bi-nasal sector and visual evoked potentials' amplitude could help to predict the restoration of parvocellular pathway traffic after decompression.
RESUMO
Introducción: El mieloma múltiple es una neoplasia maligna de células B caracterizada por una proliferación clonal incontrolada de células plasmáticas. Se define como mortalidad precoz en el mieloma múltiple de nuevo diagnóstico, al porcentaje de muerte que ocurre dentro de los primeros seis meses y afecta entre el 10 y 14 % de los casos. Los biomarcadores han evolucionado desde la caracterización del tumor hasta el reconocimiento de las aberraciones cromosómicas y moleculares que desempeñan un papel en la supervivencia. Objetivo: Describir los principales predictores identificados con relación a la mortalidad precoz y su función en la patogénesis de la enfermedad. Métodos: Se analizó la literatura científica publicada. Se utilizaron motores de búsqueda como Google Scholar, PubMed y ScienceDirect. Se consultaron un total de 80 artículos y se incluyeron 52, en su mayoría de los últimos cinco años. Análisis y síntesis de la información: Se evidenciaron mecanismos genéticos y epigenéticos que contribuyen de manera decisiva en la mortalidad precoz de pacientes con mieloma múltiple de nuevo diagnóstico. Conclusiones: El aumento del riesgo de mortalidad precoz en pacientes con mieloma múltiple de nuevo diagnóstico está asociado a factores clínicos y biológicos, por lo que existe la necesidad de estratificación de los pacientes para un manejo personalizado que impone el uso de datos clínicos y biológicos de una forma integrada.
Introduction: Multiple Myeloma is a malignant B-cell neoplasm characterized by uncontrolled clonal proliferation of plasma cells. Early mortality in newly diagnosed Multiple Mieloma is defined as the percentage of death that occurs six months or less after diagnosis and, it affects 10 to 14 % of the cases. Biomarkers have evolved from the characterization of tumor to the recognition of chromosomal and molecular aberrations that play a rol in survival. Objective: To describe the main predictors identified related to early mortality and their role in the pathogenesis of the disease. Methods: The scientific literature was analyzed using search engines such as Google Scholar, PubMed and ScienceDirect. Consulted articles were 80 and included articles were 52, mostly from the last five years. Analysis and information synthesis: Genetic and epigenetic mechanisms that contribute decisively in the early mortality in new diagnosis Multiple Myeloma patients were evidenced. Conclusions: The increased risk of early mortality in patients with newly diagnosed Multiple Myeloma is associated with clinical and biological factors and there is a need to stratify patients in terms of early mortality risk for personalized management, for which it is imposed the use of clinics and biological data in an integrative way.
